Advertisement

Topics

FTase Inhibition Holds Promise for RAS Targeting and Beyond

16:13 EDT 15 May 2018 | OncLive

Although mutant RAS has proved to be a challenging therapeutic target, recent success with tipifarnib, a biologically active drug known as a farnesyltransferase inhibitor, brings promise for treating solid tumors and hematological malignancies.

Original Article: FTase Inhibition Holds Promise for RAS Targeting and Beyond

NEXT ARTICLE

More From BioPortfolio on "FTase Inhibition Holds Promise for RAS Targeting and Beyond"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

Pharmacy
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...